
1. hum gene ther clin dev. 2015 mar;26(1):5-14. doi: 10.1089/humc.2014.153. epub
2015 feb 12.

translational data adeno-associated virus-mediated gene therapy of
hemophilia b dogs.

nichols tc(1), whitford mh, arruda vr, stedman hh, kay ma, high ka.

author information: 
(1)1 francis owen blood research laboratory, department pathology and
laboratory medicine, university north carolina chapel hill , chapel hill,
nc 27516.

preclinical testing new therapeutic strategies relevant animal models an
essential part drug development. choice animal models disease that
are used studies driven strength translational data for
informing safety, efficacy, success failure human clinical
trials. hemophilia b monogenic, x-linked, inherited bleeding disorder that
results absent dysfunctional coagulation factor ix (fix). regarding
preclinical studies adeno-associated virus (aav)-mediated gene therapy for
hemophilia b, dogs severe hemophilia b (<1% fix) provide well-characterized 
phenotypes genotypes species-specific transgene expressed
in mixed genetic background. correction hemophilic coagulopathy by
sustained expression fix, reduction bleeding events, comprehensive
assessment humoral cell-mediated immune responses expressed
transgene recombinant aav vector feasible end points dogs.
this review compares preclinical studies aav vectors used treat dogs
with hemophilia b results obtained subsequent human clinical trials
using muscle- liver-based approaches.

doi: 10.1089/humc.2014.153 
pmcid: pmc4442577
pmid: 25675273  [indexed medline]

